Anavex's Alzheimer's Drug Faces Setback, U.S. Talks Continue

Anavex Life Sciences Alzheimers drug candidate, blarcamesine, received a negative vote from the European Medicines Agency, causing a significant stock drop. The company plans to request a re-examination and is also seeking a meeting with the FDA to discuss U.S. clinical trial results. Blarcamesine is an oral medication with a unique mechanism and a good safety profile, potentially offering a new treatment option for early Alzheimers patients. Anavex is also developing treatments for other brain and nervous system disorders.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.